Please find all available sponsorship options for the 2022 Conference here:
We would like to thank the sponsors of the 9th International mRNA Health Conference:
Founded in February 2009 – Vancouver, Canada-based Acuitas Therapeutics is a private biotechnology company that specializes in the development of delivery systems for nucleic acid therapeutics based on lipid nanoparticles (LNP). Acuitas partners with pharmaceutical and biotechnology companies and academic institutes to advance nucleic acid therapeutics to the clinic and to the marketplace. The company’s LNP have emerged as a highly effective delivery system, first approved for patients in Onpattro™ with partner Alnylam Pharmaceuticals and, most recently, in the BioNTech/Pfizer COVID-19 vaccine COMIRNATY®.
Arcturus Therapeutics Holdings Inc. is a leading clinical-stage messenger RNA medicines company focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases.
BioNTech is a next generation immunotherapy company pioneering novel therapies for cancer and other serious diseases. The company exploits a wide array of computational discovery and therapeutic drug platforms for the rapid development of novel biopharmaceuticals. Its broad portfolio of oncology product candidates includes individualized and off-the-shelf mRNA-based therapies, innovative chimeric antigen receptor T cells, bi-specific checkpoint immuno-modulators, targeted cancer antibodies and small molecules. Based on its deep expertise in mRNA vaccine development and in-house manufacturing capabilities, BioNTech and its collaborators are developing multiple mRNA vaccine candidates for a range of infectious diseases alongside its diverse oncology pipeline. BioNTech has established a broad set of relationships with multiple global pharmaceutical collaborators, including Genmab, Sanofi, Bayer Animal Health, Genentech, a member of the Roche Group, Regeneron, Genevant, Fosun Pharma, and Pfizer.
CureVac is a global biopharmaceutical company in the field of messenger RNA (mRNA) technology, with more than 20 years of expertise in developing and optimizing the versatile biological molecule for medical purposes. The principle of CureVac’s proprietary technology is the use of non-chemically modified mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a broad range of diseases. Based on its proprietary technology, the Company has built a deep clinical pipeline across the areas of prophylactic vaccines, cancer therapies, antibody therapies, and the treatment of rare diseases. CureVac had its initial public offering on the New York Nasdaq in August 2020. It is headquartered in Tübingen, Germany, and employs more than 700 people at its sites in Tübingen, Frankfurt, and Boston, USA. Further information can be found at www.curevac.com.
Cytiva is a global life sciences leader dedicated to advancing and accelerating therapeutics. Cytiva is a trusted partner to customers that undertake life-saving activities ranging from biological research to developing innovative vaccines, biologic drugs, and novel cell and gene therapies. Cytiva brings speed, efficiency and capacity to research and manufacturing workflows, enabling the development, manufacture and delivery of transformative medicines to patients. Visit cytiva.com for more.
You want to scale and deliver your mRNA vaccine to the world quickly. Our company seeks to understand the goals you have for your vaccine and then provide the solutions that will help you overcome your development and manufacturing challenges. Our process development engineers, scientists, regulatory experts and broad portfolio of best-in-class products and services can help you improve process economics, accelerate time to market, and mitigate production risks. Our collaborative global vaccine capabilities will take your innovation from discovery to full-scale GMP-manufacturing quickly, safely, and cost-effectively. Discover how expertise, empowered by collaboration, can refine mRNA approaches, and overcome manufacturing challenges
PNI is a global leader in ushering in the next wave of genetic medicines in infectious diseases, cancer, and rare diseases. We work with the world’s leading drug developers to understand disease and create the therapeutics and vaccines that will define the future of medicine. PNI offers proprietary technology platforms and comprehensive expertise to enable researchers to translate disease biology insights into non-viral genetic medicines.
Established in the mid 1970s, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, sample preparation for next generation sequencing, synthetic biology, glycobiology, epigenetics, and RNA analysis. Additionally, NEB is focused on strengthening alliances that enable new technologies to reach key market sectors, including the development of molecular diagnostics, as well as nucleic acid vaccines. New England Biolabs is a privately held company, headquartered in Ipswich, MA (USA), and represented in Europe by subsidiaries in Germany, France and the UK.
Thermo Fisher Scientific supports developers and manufacturers of nucleic acid therapeutics and vaccines with a proven product portfolio that spans from discovery to development to global scale commercial production. Starting with therapeutic grade raw materials, we provide the products and services necessary to bring a nucleic acid therapeutic to market. Our portfolio includes products for in vitro transcription, oligonucleotide synthesis, purification, analytical and QC testing, single-use technologies, and comprehensive measurement and control solutions.
Polymun Scientific GmbH
is a private Austrian company, located in Klosterneuburg, offering contract development and manufacturing of biopharmaceuticals as well as development and production of LNP and liposomal formulations. Its patented liposome/LNP technology allows efficient manufacturing of constantly high quality in small and large scale. Over the last 15 years, Polymun has guided LNP and liposomal formulations into clinical trials, amongst them DNA and different kinds of RNA formulations. A prominent example is Polymun’s contribution to the BioNTech/Pfizer Covid-19 vaccine. Polymun is an FDA- and EMA-inspected manufacturer conducting several own R&D projects. For more information, please visit www.polymun.com
A major focus of research at Samyang Holdings Biopharmaceuticals Division has been the application of new DDS and innovative drugs applying DDS technologies have successfully been developed. Genexol® PM and Nanoxel® M are two approved cancer drugs that use nano-polymer DDS. Samyang Holdings Biopharmaceutical is also the first in the world to succeed in mass producing Pacliaxel, the active pharmaceutical ingredient of Genexol PM and others, through the application of a plant cell culture technology developed internally.
Samyang Holdings Biopharmaceuticals Division has also developed medical patches for the treatment of pain for cancer patients, smoking cessation, and anti-inflammatory analgesia , via the application of TDS (Transdermal Delivery System) technology.
Innovative technologies that effectively deliver biological materials such as RNA, and DNA and virus to selective tissues have been an area of recent focus of research. In addition to drugs based on monoclonal antibody, antibody-drug conjugate and recombinant protein platforms that Samyang Holdings Biopharmaceutical is developing, drugs developed with these innovative drug delivery systems are expected to expand new treatment opportunities for cancer patients.
TriLink BioTechnologies, part of Maravai LifeSciences, is a best-in-class contract development and manufacturing organization (CDMO) for the synthesis of nucleic acids, including NTPs and mRNA capping analogs. TriLink’s proprietary mRNA capping technology, CleanCap®, simplifies mRNA manufacturing by removing additional enzyme-dependent steps, resulting in higher capping efficiency and improved yields over traditional co-transcriptional capping methods.
TriLink’s CDMO solutions include a range of manufacturing grade products, from discovery-grade to a customizable GMPLink™ intermediate grade, to full GMP-grade with scale-up and technology transfer capabilities. TriLink operates quality systems in compliance with ICH Q7, GMP Guidance for Active Pharmaceutical Ingredients, Section 19, APIs for Use in Clinical Trials, and ISO 9001:2015 standards.
TriLink continues to expand its cGMP capacity at its new headquarters in San Diego, California, with scale-up expertise and unique production capabilities of mRNA, oligonucleotides, and plasmid DNA for biopharmaceutical companies focused on therapeutic, vaccine, and diagnostic breakthroughs.
Axolabs is a world leading service provider in oligonucleotide- & mRNA-based therapeutics. We are the single organisation to deliver best solutions for nucleic acid therapeutics’ development, ranging from lead ID, across all clinical stages, to commercial supply.
For mRNAs, Axolabs’ portfolio includes LC-MS based methods to confirm mRNA identity, capping efficacy as well as poly(A)tail length & polydispersity characterisation. In addition, mRNA integrity & purity can be assessed by HPLC/UPLC analysis. LipidNanoParticle formulations can be characterised for size, polydispersity, surface charge & payload encapsulation together with quantitative analysis of lipid & mRNA- composition. All analytical services can be conducted under GMP.
Services to analyse pharmacological properties of mRNA formulations include in vitro & in vivo analysis of activity & safety, as well as pharmacokinetics & biodistribution to support GLP-Tox studies as well as clinical trials.
CerTest VACCINES is a division of CerTest Biotec, directed to the development of mRNA vaccines.
Since its founding back in 2002, CerTest Biotec has been mainly focused on the development of innovative solutions for the diagnosis of a wide range of infectious diseases. The extensive work behind each and all of these developments has enabled us to acquire vast experience in a great variety of pathogens, such as RSV, Influenza or SARS-CoV-2.
This previous knowledge put us in an enviable position, as it provides us with a close understanding of these diseases. Thus, our goal is to develop RNA vaccines against these kinds of pathogens, a scope that could be broadened to other applications, such as cancer immunotherapy. The advances resulting from our efforts will hopefully be a positive contribution to this field and help face other potential threats in the future.
Eclipse Bio has developed multiple world-class RNA genomics products used by biopharma and academic customers around the world to map their RNA targets and RNA binding proteins with unmatched clarity. We continue to develop innovative RNA genomics and epigenetics solutions that solve current and future challenges in science and medicine.
Our innovative standard and customizable solutions bring new and deeper insights to the RNA interactome by providing more accurate, reproducible and useable data for our customers.
Eurogentec is an international company founded in 1985 and part of Kaneka Corp. since 2010.
Headquartered in Liege (Belgium) it provides products and services to scientists involved in the life science research, molecular diagnostics and therapeutic developments.
Eurogentec has production sites in Europe and United States of America.
The company is recognized as one of the major suppliers in the field of genomics and proteomics as well as a trusted US FDA inspected Contract Development and Manufacturing Organization (CDMO) for the bio-production of pharmaceuticals (vaccines and medicines).
Hongene Biotech Corporation was established in 2001 as a R&D organization and has since become a manufacturer with state-of-art facilities in the fields of nucleosides, nucleotides and phosphoramidites.
Having main operations in Shanghai, China at the start, today the company also has offices and laboratories in USA and Japan. Hongene supplies only the best quality products at competitive price to customers worldwide. Through collaborations with pharmaceutical diagnostic and biotechnology companies, Hongene is continuously developing new products in this area of science.
At Hongene our experts are also happy to offer custom synthesis products essential for your R&D, helping to bring your products to market more efficiently. Through continuous innovation, improvement of manufacturing technologies, the tightest quality control and devoted technical team and services, we aim to help our customers to achieve their goals efficiently and economically.
Evonik Health Care is a global innovation hub for the world’s leading life science companies. As a leading CDMO for advanced oral and parenteral drug delivery solutions, Evonik Health Care supports customers along the entire value chain from early development to commercial manufacturing. Evonik Health Care is also one of the world’s largest CMOs for active pharmaceutical ingredients (APIs) and intermediates, as well as a supplier of amino acids, cell culture ingredients and medical device excipients.
Being experts in nanoparticle size characterization, they are the inventors of the NanoFlowSizer: a unique, non-invasive nanoparticle size instrumentation for real-time measurement.
The NanoFlowSizer thanks it’s unique properties of being the only instrument capable of measuring particle size and size distribution of turbid nanosuspensions in flow, without the need for sample treatment or dilution.
The InProcess-LSP team has a great experience and interest in PAT science and a strong background in process and product development.
Our analytical capabilities include low-coherence interferometry; UV/VIS, NIR and Raman Spectroscopy, high resolution microscopes and NIR Imaging.
In addition we have in-house capabilities for HPH, crystallization and nanomilling to support ongoing PAT developments and customer applications.
InProcess-LSP : a provider of groundbreaking innovations for PAT.
Lipoid is a growing, internationally active company and industry pioneer and has been setting standards in the field of phospholipids – multifunctional and enabling excipients with outstanding performance, highest quality and unrivalled safety profile – for over 40 years. As a leading supplier of natural and synthetic phospholipids at industrial scale for pharmaceutical applications, especially for complex dosage forms like liposomes, lipid nanoparticles and emulsions.
The products meet the highest standards set by regulatory authorities and the pharmaceutical industry. Lipoid’s phospholipids are also used in health nutrition and skin care products. Lipoid is primarily owned by the Lipoid Stiftung and a founding member of the Phospholipid Research Center.
Building on decades of experience as a diagnostics and pharmaceutical manufacturer, Roche CustomBiotech provides a broad range of products for manufacturing of enzymes, antibodies and biopharmaceuticals. CustomBiotech offers enzymes for cleavage and glycoengineering of proteins, PCR-based kits for rapid microbiological QC for biopharmaceutical production. Cedex Analyzers allow the monitoring of substrates and metabolites and bacterial and mammalian cell growth and viability. Roche CustomBiotech delivers high quality raw materials for mRNA therapeutics (Pharma grade), products and services for biopharmaceutical, cell therapy, or in vitro diagnostics business, customized to your unique quality and regulatory needs all over the globe. Focus on the development of your drug and rely on us and our raw materials to facilitate every step on your path to market.
ST Pharm is a subsidiary company of Dong-A Socio Group, Korea’s top pharmaceutical company with a history of 80 years. Since 1983, ST Pharm has been offering excellent custom manufacturing services of oligonucleotides and small molecule APIs to meet clients’ high expectation for their use in pharmaceutical development in compliance to cGMP requirements. The expansion of oligonucleotide production capabilities became a new growth engine for the future pharmaceutical industry. In particular, the expansion of Oligonucleotide Plant in 2018 has secured its place as Global Top 3 oligonucleotide manufacturer. Based on the in-depth knowledge from manufacturing nucleoside to oligonucleotide, it has enabled ST Pharm to leverage its know-how into manufacturing polynucleotide, the mRNA. ST Pharm has in-house mRNA platform which enables development and production of mRNA vaccines.
We are a Regional Boutique clinical research organization (CRO) with presence in Latin America.
Since 2012, we have been involved in several studies focused on vaccine preventable diseases.
We provided innovative solutions, managing and monitoring activities of turnkey vaccine clinical trial services, from selecting the most appropriate trial sites with a representative patient population, to choosing to work with the right partners.